

Tuesday, March 10		
8:00AM-10:00AM	Session 1: Setting the Conference Context and Drivers Chair: Bob Adamson (Wyeth) Keynote by Rob Garnick (Lone Mountain Biotechnology) Keynote by Janice Reichert (Tufts University)	
		Recent Developments in Biosimilars Development Trends for Biotherapeutics
10:30AM-12:30PM	Session 2: Emerging, "Disruptive" Technologies: Disruptive Science and Technology Chairs: Gordon Moore (Centocor), Brian Kelley (Genentech) and Jim Swartz (Stanford) Stefan Wildt (Merck) Annie De Groot (EpiVax) Bill Warren (Vaxdesign) Karyn O'Neil (Cyntrix)	
		Glycoengineered Yeast: A Versatile Glycoprotein Expression Platform Immunology Models In Vitro Biomimetic Human Immune System Models for Drug Assessment: MIMIC System Centyrin Alternative Scaffolds: A New Biotherapeutic Platform for J&J
2:00PM-4:30PM	Session 3: Cutting-Edge Analytical Techniques Chairs: Rohin Mhatre (BiogenIdec) and Tom Porter (Wyeth) Tom Laue (University of New Hampshire) Kermit K. Murray (Louisiana State University) Igor Kaltashov (University of Massachusetts, Amherst) Steve Cohen (Waters Corp.) Judy Chou (Genentech)	
		Advances in Analytical Ultracentrifugation and Analytical Electrophoresis Coupling Microfluidic Chips to MALDI Mass Spectrometry Mass Spectrometry-Based Strategies to Study Protein Architecture, Dynamics, and Binding Chromatographic Analysis for Biopharmaceuticals: Current Trends and Future Prospects High Throughput Analytical Methods for Bioprocess Development
4:30-6:00PM	Poster Session Chair: Louanne Hann (Wyeth)	
Wednesday, March 11		
8:00AM-10:00AM	Session 4: Accelerated Cell Culture Process Development Chairs: Timothy Charlebois (Wyeth) and Rohini Deshpande (Amgen) Florian Wurm (ETH-Zurich) Greg Hillier (Wyeth) Luhong He (Lilly) Denny Kraichely (Centocor)	
		Transient Expression in CHO Cells Cell Culture Yield Improvements: Integrated Technologies Resulting in Leaps in Productivity Quantitative Analysis of Transfected MoAb Genes in Recombinant Single Cells and its Application in Cell Line Generation Fluorescent Protein G Methylcellulose Screening -- A More Predictive Approach to Isolate High-Producing Candidate Manufacturing C
10:30AM-12:30PM	Session 5: Critical Quality Attributes, Specifications and Comparability Chairs: Reed Harris (Genentech) and Paul Tsang (Amgen) Sally Anliker (Lilly) Patrick Swann (FDA) Paul Motchnik (Genentech) Izzydor Apostol (Amgen)	
		Connecting CQAs to Control Strategies for Bioproducts Regulatory Considerations for Evaluating Product Quality Defining and Assigning CQAs Analytical Perspective on Product Specification Lifecycle During Biotech Development
2:00PM-4:30PM	Session 6: High Throughput Protein Formulation Development Chairs: David Volkin (Centocor) and Bruce Kerwin (Amgen) Juan Alvarez (TransForm Pharmaceuticals) Russ Middaugh (University of Kansas, Department of Pharmacy) Mark Manning (Legacy Biodesign) Byeong Chang (Symyx Technologies Inc) Albert Lee (Genentech)	
		Application of High Throughput Technologies in the Development of Biopharmaceuticals An Empirical Phase Diagram/High Throughput Screening Approach to the Formulation of Macromolecular Systems Efficient and Rationale Development of Liquid Formulations of Biopharmaceuticals A Parallel, Microscale, Automated Approach to (Pre)Formulation and Stress Test Studies for Large Molecules High Throughput Formulation Screening Using Rapid Stress Methods
4:30-6:00PM	Poster Session Chair: Louanne Hann (Wyeth)	
6:00-9:00PM	Banquet Keynote by John Carpenter (University of Colorado)	
		Protein Aggregation: Causes, Consequences, Control and Challenges
Thursday, March 12		
8:00AM-10:30AM	Session 7: Emerging, "Disruptive" Technologies: Technology Options and Analysis Chairs: Gordon Moore (Centocor), Brian Kelley (Genentech), and Jim Swartz (Stanford) Saddetin Ozturk (Centocor) Brian Hubbard (Amgen) Brian Kelley (Genentech) Tom Ransohoff (Bioprocess Consultants) 30-minute discussion	
		Facilities Based on Disposable Technology Future Directions in Purification Technology Industrialization of mAb Processing: What Hath CHO Wrought Challenges of Introduction of New Technologies
11:00AM-12:30PM	Session 8: Functional Interaction, Integration, and Synergy in Platform Development – from Amino Acid Sequence Identification to Protein Delivery Chairs: Brendon Hughes (Wyeth) and Patricia Alred (Centocor) Hubie Scoble (Wyeth) Victor Fung (Amgen) Pat Alred (Centocor)	
		BioPharma Development Platform Concepts – What's Next? Gaining Momentum From Platforms - How Other Functions Took a Good Idea and Made it Better Applying QbD Principles as a Function of Product Maturity
2:00PM-4:30PM	Session 9: Rapid and Economic Purification Process Development Chairs: Jorg Thommes (Biogen Idec) and Paul Mensah (Pfizer) Sam Guhan (Amgen) Lynn Conley (Biogen Idec) Christopher J. Gallo (Wyeth BioPharma) Tangir Ahamed (SynCo Bio Partners) Karol Lacki (GE Healthcare)	
		How Not to Squander Cell Culture Titer Improvements During Downstream Processing Using Partition Designs to Reduce Purification Process Characterization Time Development of a Late Phase Off-Platform Manufacturing Process Within a Platform Development Timeline The Use and Misuse of Rules-of-Thumbs for Rapid Development of Ion-Exchange Chromatography Process Development and Scale-Up of a Downstream Process for a Monoclonal Anti-Body: A Case Study